{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:30:35Z","timestamp":1793712635085,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024087","name":"Theramex HQ UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016288","name":"Kissei Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","award":["5\/4\/150\/5"],"award-info":[{"award-number":["5\/4\/150\/5"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.fertnstert.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:04:36Z","timestamp":1750331076000},"page":"737-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-206X","authenticated-orcid":false,"given":"Jacques","family":"Donnez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Petraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Carmona","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Madeleine","family":"Dolmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2025.06.016_bib1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2017.09.004","article-title":"Epidemiology and risk factors of uterine fibroids","volume":"46","author":"Pavone","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2024.02.048","article-title":"Pathogenesis of uterine fibroids: current understanding and future directions","volume":"122","author":"Dolmans","year":"2024","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/humrep\/deh309","article-title":"Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black women\u2019s health study","volume":"19","author":"Wise","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1210\/endrev\/bnab039","article-title":"Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment","volume":"43","author":"Yang","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00270-011-0228-5","article-title":"Uterine artery embolization versus myomectomy: impact on quality of life\u2013results of the FUME (fibroids of the uterus: myomectomy versus embolization) trial","volume":"35","author":"Manyonda","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib9","article-title":"Fibroids: diagnosis and management","volume":"351","author":"Lumsden","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib10","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.3390\/jcm10194389","article-title":"Conservative management of uterine fibroid\u2013related heavy menstrual bleeding and infertility: time for a deeper mechanistic understanding and an individualized approach","volume":"10","author":"Dolmans","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with Relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(22)01475-1","article-title":"Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials","volume":"400","author":"Donnez","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.fertnstert.2024.12.031","article-title":"Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials","volume":"123","author":"Donnez","year":"2025","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib18","doi-asserted-by":"crossref","first-page":"237.e1","DOI":"10.1016\/j.ajog.2023.10.030","article-title":"Relugolix combination therapy in Black\/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study","volume":"230","author":"Stewart","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib20","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.ajog.2023.08.030","article-title":"LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids","volume":"229","author":"Al-Hendy","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib21","first-page":"285","article-title":"Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials","volume":"5","author":"Simon","year":"2024","journal-title":"F S Rep"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib22","doi-asserted-by":"crossref","first-page":"320.e1","DOI":"10.1016\/j.ajog.2022.11.1278","article-title":"Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials","volume":"228","author":"Stewart","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.fertnstert.2023.07.012","article-title":"Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials","volume":"120","author":"Donnez","year":"2023","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73151-y","article-title":"Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study","volume":"14","author":"Muzii","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/13625187.2011.591456","article-title":"Effective treatment of heavy and\/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest","volume":"16","author":"Fraser","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.fertnstert.2024.02.049","article-title":"Uterine fibroid-related infertility: mechanisms and management","volume":"122","author":"Donnez","year":"2024","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib27","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.3390\/jcm9123948","article-title":"Uterine fibroids and progestogen treatment: lack of evidence of its efficacy: a review","volume":"9","author":"Donnez","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/17425255.2024.2441981","article-title":"The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications","volume":"21","author":"Barretta","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.fertnstert.2025.06.016_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225005217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225005217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:43:02Z","timestamp":1777459382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028225005217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0015028225005217"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.06.016","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}